Since the author’s last update in August 2025, Pfizer has outperformed the S&P 500 by approximately 12 percentage points through year-end, propelled by a combination of revenue growth and margin expansion. In Q3 2025, adjusted operating margin exceeded 36%, up from 33% a year earlier, reflecting aggressive cost‐savings initiatives that have delivered over $2.1 billion in annualized efficiencies. Concurrently, global revenue climbed 5% year‐over‐year, underpinned by strength in core vaccine franchises and incremental gains in the hospital portfolio. These improvements have reset investor expectations, with consensus earnings per share estimates rising by 8% for 2026 since September 2025.

Pfizer’s precision oncology suite continues to mature, with the Phase 3 BRAFTOVI trial in BRAF V600E–mutated colorectal cancer achieving its primary endpoint of progression‐free survival in December 2025. Additionally, the PADCEV plus Keytruda combination secured FDA approval for first‐line urothelial carcinoma in November 2025, broadening its addressable market by over 45,000 patients annually in the U.S. On the metabolic front, the novel oral GLP‐1 candidate MET-097i enters pivotal Phase 3 studies in Q2 2026, targeting an addressable obesity market valued at over $40 billion. Management projects peak annual sales of $4 billion to $6 billion for the obesity program, contingent on positive topline data expected in late 2027.

With a forward dividend yield of 6.7%, Pfizer ranks among the top five highest-yielding constituents of the S&P 500 ex-REITs. The company has maintained a payout ratio below 50% of projected 2026 adjusted earnings, ensuring dividend coverage even under conservative margin assumptions. In addition to returning over $10 billion in dividends last year, Pfizer repurchased $5 billion of its common shares, representing roughly 2% of the float. Management has reiterated a commitment to allocate 50% of free cash flow to dividends and repurchases while reserving capacity for strategic bolt-on acquisitions in high-growth therapeutic areas.